Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Assess immunogenicity, safety & reactogenicity of a 4th dose of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC at 15-24 months & of a dose of Mencevax™ ACWY at 24-30 months in subjects primed with 3 doses of Tritanrix™-HepB/Hib-MenAC
Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine
104727
NCT00136604
Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis
Phase 3
 
An annotated case report form is not available for this study. A blank case report form will be provided.
October 2014

Powered by ideaPoint, Inc.